Lucía Inglada-Pérez

Lucía Inglada-Pérez

Auto-generated profile, based on publicly available information

Lucía Inglada-Pérez

UNED

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ICIñaki Comino-Mendez
Iñaki Comino-Mendez
FGFrancisco J Gracia-Aznárez
Francisco J Gracia-Aznárez
Francesca SchiaviFrancesca Schiavi
Francesca Schiavi
Iñigo LandaIñigo Landa
Iñigo Landa
LLLuis J Leandro-García
Luis J Leandro-García
Alberto CasconAlberto Cascon
Alberto Cascon

14 May 2012 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NBNelly Burnichon
Nelly Burnichon
Alberto CasconAlberto Cascon
Alberto Cascon
Francesca SchiaviFrancesca Schiavi
Francesca Schiavi
NMNicole Paes Morales
Nicole Paes Morales
ICIñaki Comino-Mendez
Iñaki Comino-Mendez
MRMercedes Robledo
Mercedes Robledo
Purpose: Pheochromocytomas (PCC) and paragangliomas (PGL) are genetically heterogeneous neural crest–derived neoplasms. Recently we identified germline mutations in a new tumor suppressor susceptibility gene, MAX (MYC-associated factor X), which predisposes carriers to PCC. How MAX mutations contribute to PCC/PGL and associated phenotypes remain unclear. This study aimed to examine the prevalence and associated phenotypic features of germline and somatic MAX mutations in PCC/PGL. Design: We sequenced MAX in 1,694 patients with PCC or PGL (without mutations in other major susceptibility genes) from 17 independent referral centers. We screened for large deletions/duplications in 1,535 patients using a multiplex PCR-based method. Somatic mutations were searched for in tumors from an additional 245 patients. The frequency and type of MAX mutation was assessed overall and by clinical characteristics. Results: Sixteen MAX pathogenic mutations were identified in 23 index patients. All had adrenal tumors, including 13 bilateral or multiple PCCs within the same gland (P < 0.001), 15.8% developed additional tumors at thoracoabdominal sites, and 37% had familial antecedents. Age at diagnosis was lower (P = 0.001) in MAX mutation carriers compared with nonmutated cases. Two patients (10.5%) developed metastatic disease. A mutation affecting MAX was found in five tumors, four of them confirmed as somatic (1.65%). MAX tumors were characterized by substantial increases in normetanephrine, associated with normal or minor increases in metanephrine. Conclusions: Germline mutations in MAX are responsible for 1.12% of PCC/PGL in patients without evidence of other known mutations and should be considered in the genetic work-up of these patients. Clin Cancer Res; 18(10); 2828–37. ©2012 AACR.

4 November 2010 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
SLS. Leskela
S. Leskela
LLL. J. Leandro-Garcia
L. J. Leandro-Garcia
MMM. Mendiola
M. Mendiola
JBJorge Barriuso
Jorge Barriuso
LIL. Inglada-Perez
L. Inglada-Perez
Cristina Rodriguez-AntonaCristina Rodriguez-Antona
Cristina Rodriguez-Antona
Ovarian cancer remains one of the leading causes of cancer deaths. Thus, new biomarkers predictive of response to the standard paclitaxel–carboplatin treatment are needed to improve chemotherapy strategies. MicroRNAs have the potential to modify drug outcomes. Based on this, we have demonstrated in this study that patients with a high expression of the miR-200 family show low levels of β-tubulin class III in ovarian carcinoma. In addition, we have established the clinical relevance of these microRNAs for ovarian cancer patients' treatment response and survival. In a well-characterized series of 72 ovarian carcinomas, the expressions of miR-141, miR-200a, miR-200b, miR-200c, and miR-429 were quantified by quantitative reverse transcription-PCR, and the protein content of β-tubulin isotypes I, II, and III was determined by immunohistochemistry. The relationship between these microRNAs, β-tubulin expression, response to paclitaxel-based treatment, progression-free survival (PFS) and overall survival was determined. While isotype I had constant high levels, protein expression of β-tubulins II and III was mutually exclusive. Low tumoral miR-200 expression was significantly associated with high β-tubulin III protein content (P values range, 0.047–2.0, P values 0.051, 0.054, and 0.079 for miR-200c, miR-141, and miR-429 respectively, multivariate analysis). In conclusion, miR-200 family members affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.

1 August 2015 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
NMNerea Matamala
Nerea Matamala
MVMaría Teresa Vargas
María Teresa Vargas
RGRicardo González-Cámpora
Ricardo González-Cámpora
RMRebeca Miñambres
Rebeca Miñambres
JAJosé Ignacio Arias
José Ignacio Arias
JBJavier Benítez
Javier Benítez
BACKGROUND: The identification of novel biomarkers for early breast cancer detection would be a great advance. Because of their role in tumorigenesis and stability in body fluids, microRNAs (miRNAs) are emerging as a promising diagnostic tool. Our aim was to identify miRNAs deregulated in breast tumors and evaluate the potential of circulating miRNAs in breast cancer detection. METHODS: We conducted miRNA expression profiling of 1919 human miRNAs in paraffin-embedded tissue from 122 breast tumors and 11 healthy breast tissue samples. Differential expression analysis was performed, and a microarray classifier was generated. The most relevant miRNAs were analyzed in plasma from 26 healthy individuals and 83 patients with breast cancer (36 before and 47 after treatment) and validated in 116 healthy individuals and 114 patients before treatment. RESULTS: We identified a large number of miRNAs deregulated in breast cancer and generated a 25-miRNA microarray classifier that discriminated breast tumors with high diagnostic sensitivity and specificity. Ten miRNAs were selected for further investigation, of which 4 (miR-505-5p, miR-125b-5p, miR-21-5p, and miR-96-5p) were significantly overexpressed in pretreated patients with breast cancer compared with healthy individuals in 2 different series of plasma. MiR-505-5p and miR-96-5p were the most valuable biomarkers (area under the curve 0.72). Moreover, the expression levels of miR-3656, miR-505-5p, and miR-21-5p were decreased in a group of treated patients. CONCLUSIONS: Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.

1 December 2010 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
Elena López-JiménezElena López-Jiménez
Elena López-Jiménez
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
LLL. Javier Leandro-García
L. Javier Leandro-García
IMIván Muñoz
Iván Muñoz
Francesca SchiaviFrancesca Schiavi
Francesca Schiavi
Alberto CasconAlberto Cascon
Alberto Cascon
The six major genes involved in hereditary susceptibility for pheochromocytoma (PCC)/paraganglioma (PGL) (RET, VHL, NF1, SDHB, SDHC, and SDHD) have been recently integrated into the same neuronal apoptotic pathway where mutations in any of these genes lead to cell death. In this model, prolyl hydroxylase 3 (EglN3) abrogation plays a pivotal role, but the molecular mechanisms underlying its inactivation are currently unknown. The aim of the study was to decipher specific alterations associated with the different genetic classes of PCCs/PGLs. With this purpose, 84 genetically characterized tumors were analyzed by means of transcriptional profiling. The analysis revealed a hypoxia-inducible factor (HIF)-related signature common to succinate dehydrogenase (SDH) and von Hippel-Lindau (VHL) tumors, that differentiated them from RET and neurofibromatosis type 1 cases. Both canonical HIF-1α and HIF-2α target genes were overexpressed in the SDH/VHL cluster, suggesting that a global HIF deregulation accounts for this common profile. Nevertheless, when we compared VHL tumors with SDHB cases, which often exhibit a malignant behavior, we found that HIF-1α target genes showed a predominant activation in the VHL PCCs. Expression data from 67 HIF target genes was sufficient to cluster SDHB and VHL tumors into two different groups, demonstrating different pseudo-hypoxic signatures. In addition, VHL-mutated tumors showed an unexpected overexpression of EglN3 mRNA that did not lead to significantly different EglN3 protein levels. These findings pave the way for more specific therapeutic approaches for malignant PCCs/PGLs management based on the patient’s genetic alteration.

15 December 2010 in JAMA
Verified
Journal Article
Open access
PDF file
LYLi Yao
Li Yao
Francesca SchiaviFrancesca Schiavi
Francesca Schiavi
Alberto CasconAlberto Cascon
Alberto Cascon
YQYuejuan Qin
Yuejuan Qin
LILucia Inglada-Pérez
Lucia Inglada-Pérez
PDPatricia Dahia
Patricia Dahia
Pheochromocytomas and paragangliomas are chromaffin cell tumors of neural crest origin that arise from the adrenal medulla or extra-adrenal sympathetic paraganglia, respectively, and are frequently catecholamine secreting.1 These tumors are usually benign and can occur as a single entity or as part of various hereditary tumor syndromes. Genetically, pheochromocytomas and paragangliomas are heterogeneous, with at least one-third of cases resulting from germline but not somatic mutations in 1 of several independent genes: RET, VHL, NF1, and succinate dehydrogenase (SDH) subunit B, C, and D genes.2-5 More recently, other candidate susceptibility genes have also been reported, including KIF1Bβ,6,7EgIN1/PHD2,8SDHAF2,9,10 and SDHA,11 although these findings remain restricted to 1 or 2 occurrences of the reported mutations. Despite this broad spectrum of susceptibility genes, the molecular basis for the majority of pheochromocytomas and paragangliomas, including most of the sporadic and rare familial cases, remains unknown. These observations support the existence of additional pheochromocytoma susceptibility genes, which may account for some of the genetically undefined cases.12,13